Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rank in Stocks #33960
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Share Price
$17.15
Last synced: 2026-08-03
Market Cap
$6.51M
Change (1 day)
9.80%
Change (1 year)
289.77%
Country
US
Trade Galera Therapeutics, Inc. (GRTX)

Category

EPS for Galera Therapeutics, Inc. (GRTX)
EPS as of March 2026 TTM: $303.74
According to Galera Therapeutics, Inc. latest financial reports and stock price the company's current EPS (TTM) is $303.74. At the end of 2023 the company had a EPS of $-1.33 a decrease compared to its 2022 EPS that were of $-2.30.
EPS history for Galera Therapeutics, Inc. from 2017 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $303.74 -86,882.86%
2024 $-0.35 -73.68%
2023 $-1.33 -42.17%
2022 $-2.30 -32.35%
2021 $-3.40 14.09%
2020 $-2.98 42.58%
2019 $-2.09 71.31%
2018 $-1.22 7,770.97%
2017 $-0.02 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$17.32 -94.30%
US
$27.74 -90.87%
NL
- -
CH
- -
KR
$13.70 -95.49%
BE